Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford(South Australia Pathology), Timothy P. Hughes(Royal Adelaide Hospital), Nancy Briggs(The University of Adelaide), Haley Altamura(South Australia Pathology), David M. Ross(Flinders Medical Centre), John Reynolds(The Alfred Hospital), Jodi Prime(South Australia Pathology), Bronte A. Jamison(South Australia Pathology), Alexandra L. Yeoman(South Australia Pathology), Stuart Phillis(South Australia Pathology), Jasmina Georgievski(South Australia Pathology), Mark Hertzberg(The University of Sydney), Brad Sullivan(South Australia Pathology), David T Yeung(Royal Adelaide Hospital), John F. Seymour(The Royal Melbourne Hospital), Chani Field(South Australia Pathology)
Cited by 177
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k